ABION Inc.
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
203400 | KO
Overview
Corporate Details
- ISIN(s):
- KR7203400007
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 구로구 디지털로 242 한화비즈메트로1차 242915호, 서울특별시
- Website:
- https://abionbio.com/en/
Description
ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-14 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인신청) (cMET 표적항암제 바바메킵(ABN401)의 임상 2상 변경승인신청)
|
Korean | 14.1 KB | ||
| 2025-02-14 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인) (cMET 표적항암제 바바메킵(ABN401)의 임상 2상 변경승인)
|
Korean | 14.5 KB | ||
| 2025-02-13 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 11.4 KB | ||
| 2025-01-24 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 120.9 KB | ||
| 2025-01-10 00:00 |
주요사항보고서(타법인주식및출자증권양도결정)
|
Korean | 19.0 KB | ||
| 2024-12-30 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 130.0 KB | ||
| 2024-12-27 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인) (cMET 표적항암제 바바메킵(ABN401)의 임상 2상 변경승인)
|
Korean | 12.5 KB | ||
| 2024-12-27 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 126.6 KB | ||
| 2024-12-27 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.7 KB | ||
| 2024-12-23 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 29.0 KB | ||
| 2024-12-23 00:00 |
증권발행결과(자율공시)
|
Korean | 7.1 KB | ||
| 2024-12-18 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 28.1 KB | ||
| 2024-12-18 00:00 |
타법인주식및출자증권취득결정(자율공시)
|
Korean | 15.8 KB | ||
| 2024-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2024-12-16 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 27.8 KB |
Automate Your Workflow. Get a real-time feed of all ABION Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABION Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABION Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
